The top oncogenic RTK fusions in gastric cancer were of the FGFR family genes (total, 1.4%; FGFR2, 1.2%) and ErbB family genes (total, 0.67%; ERBB2, 0.41%, EGFR, 0.26%), with a smaller percentage of patients also harboring EPHA2 (0.15%), ALK (0.15%), MET (0.10%), RET (0.10%), and ROS1 (0.07%) fusions. The gene discussed is ALK; the disease is gastric cancer.